Introduction Plasma biomarkers—cost effective, non‐invasive indicators of Alzheimer's
disease (AD) and related disorders (ADRD)—have largely been studied in clinical research …

Introduction Plasma biomarkers will likely revolutionize the diagnostic work‐up of
Alzheimer's disease (AD) globally. Before widespread use, we need to determine if …

Abstract Introduction Blood‐based Alzheimer's disease (AD) biomarkers provide
opportunities for community studies and across ethnic groups. We investigated blood …

Background Plasma biomarkers showed a promising value in the disease diagnosis and
management of Alzheimer's disease (AD). However, profiles of the biomarkers and the …

Introduction Plasma markers have been reported to be associated with brain amyloid
burden, tau pathology, or neurodegeneration. We aimed to evaluate whether plasma …

Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …

Objective Few studies have comprehensively examined how health and disease risk
influence Alzheimer's disease (AD) biomarkers. The present study examined the association …

Introduction Plasma amyloid beta (Aβ) 1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐
tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …

Background Due to their low cost, less invasive nature, and ready availability, plasma
biomarkers of Alzheimer's disease have been proposed as one-time screening tools for …

Introduction Despite the clinical implementation, there remain significant gaps in our
knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma …